{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:09Z","timestamp":1792601469717,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["1R01FD006814-01"],"award-info":[{"award-number":["1R01FD006814-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102793","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T03:25:45Z","timestamp":1719458745000},"page":"102793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Peripheral T-cell lymphoma: From biology to practice to the future"],"prefix":"10.1016","volume":"129","author":[{"given":"Owen A.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yong Sheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctrv.2024.102793_b0005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102793_b0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2024.102793_b0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C","article-title":"Immunologic characterization of human malignant lymphomas","volume":"34","author":"Lukes","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102793_b0020","series-title":"Histopathology of Non-Hodgkin's Lymphomas","author":"Lennert","year":"1992"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102793_b0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102793_b0030","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102793_b0035","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102793_b0040","article-title":"Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102793_b0045","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102793_b0050","first-page":"1191","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective","volume":"103","author":"Bellei","year":"2018","journal-title":"Int T-Cell Project Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0055","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.3324\/haematol.2019.218305","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project","volume":"104","author":"Bellei","year":"2019","journal-title":"Haematologica"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2024.102793_b0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.1975.tb00911.x","article-title":"The histopathology of malignant lymphoma","volume":"31","author":"Lennert","year":"1975","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2024.102793_b0065","doi-asserted-by":"crossref","unstructured":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49(10):2112-35. Doi: 10.1002\/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"issue":"8580","key":"10.1016\/j.ctrv.2024.102793_b0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","article-title":"Updated Kiel classification for lymphomas","volume":"1","author":"Stansfeld","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0075","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.V68.3.663.663","article-title":"Lymphoepithelioid lymphoma (Lennert's lymphoma) is a monoclonal proliferation of helper\/inducer T cells","volume":"68","author":"Feller","year":"1986","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0080","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102793_b0085","series-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.660","article-title":"The new World Health Organization classification of lymphomas: the past, the present and the future","volume":"19","author":"Chan","year":"2001","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102793_b0095","first-page":"523","article-title":"WHO classification of lymphomas: implications for clinical practice and translational research","volume":"2009","author":"The","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102793_b0100","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102793_b0105","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0110","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-020-01093-1","article-title":"STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma","volume":"35","author":"Lobello","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102793_b0115","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.clml.2019.03.030","article-title":"p53 and beta-catenin expression predict poorer prognosis in patients with anaplastic large-cell lymphoma","volume":"19","author":"Richardson","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0120","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1038\/s41467-021-25379-9","article-title":"Super-enhancer-based identification of a BATF3\/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma","volume":"12","author":"Liang","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102793_b0130","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0140","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0145","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.3324\/haematol.2018.205880","article-title":"DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK\/STAT surrogate markers","volume":"104","author":"Onaindia","year":"2019","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102793_b0150","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","article-title":"Genetic Landscape and Classification of Peripheral T Cell Lymphomas","volume":"19","author":"Sandell","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102793_b0165","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0170","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102793_b0175","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0180","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jmoldx.2021.04.013","article-title":"Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay","volume":"23","author":"Drieux","year":"2021","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0185","article-title":"Strategy for assessing new drug value in orphan diseases: an international case match control analysis of the PROPEL study","volume":"2","author":"O'Connor","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102793_b0190","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428194.2020.1765232","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0195","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/bloodadvances.2019001114","article-title":"Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk","volume":"4","author":"Witalis","year":"2020","journal-title":"Blood Adv"},{"issue":"10168","key":"10.1016\/j.ctrv.2024.102793_b0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102793_b0205","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","article-title":"NCCN guidelines insights: T-cell lymphomas, Version 1.2021","volume":"18","author":"Horwitz","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2024.102793_b0210","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0215","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102793_b0220","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0225","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus chop in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0235","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102793_b0240","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0245","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0250","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-020-00739-0","article-title":"CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial","volume":"12","author":"Cai","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2024.102793_b0260","doi-asserted-by":"crossref","first-page":"1230629","DOI":"10.3389\/fonc.2023.1230629","article-title":"Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102793_b0265","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102793_b0270","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102793_b0275","unstructured":"ClinicalTrials.gov. Transplantation After Complete Response In Patients With T-cell Lymphoma (TRANSCRIPT). Identifier: NCT05444712. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05444712."},{"issue":"10","key":"10.1016\/j.ctrv.2024.102793_b0280","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102793_b0285","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0290","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hon.2144","article-title":"Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry","volume":"33","author":"Biasoli","year":"2015","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17474086.2019.1583102","article-title":"New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination","volume":"12","author":"Ma","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102793_b0305","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102793_b0310","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0315","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102793_b0320","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0325","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102793_b0335","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0340","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102793_b0345","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102793_b0350","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102793_b0355","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102793_b0360","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102793_b0365","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"28","key":"10.1016\/j.ctrv.2024.102793_b0370","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study","volume":"35","author":"Mosse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0375","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102793_b0385","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010441","article-title":"Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma","author":"O'Connor","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0390","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11523-019-00630-y","article-title":"Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm","volume":"14","author":"Hong","year":"2019","journal-title":"Multicenter Study Target Oncol"},{"issue":"S1","key":"10.1016\/j.ctrv.2024.102793_b0395","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.HS9.0000562676.72002.f2","article-title":"Interim update from a multi-center study of pralatrexate in Asian patients with relapsed or refractory (R\/R) peripheral T-cell lymphoma (PTCL)","volume":"3","author":"Wang","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.ctrv.2024.102793_b0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0405","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0410","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0415","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0420","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102793_b0425","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2024.102793_b0430","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0435","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","article-title":"Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature","volume":"95","author":"Zinzani","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102793_b0440","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0445","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0450","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102793_b0455","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1002\/ajh.25967","article-title":"Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy","volume":"95","author":"Bossi","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0460","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0465","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.clml.2019.03.001","article-title":"Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib","volume":"19","author":"Reed","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2024.102793_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.05.014","article-title":"Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib","volume":"83","author":"Tomlinson","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2024.102793_b0475","first-page":"4749452","article-title":"Alectinib monotherapy in isolated central nervous system relapse of ALK-positive anaplastic large cell lymphoma","volume":"2022","author":"Verran","year":"2022","journal-title":"Case Rep Hematol"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102793_b0480","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102793_b0485","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0490","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0495","doi-asserted-by":"crossref","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102793_b0500","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0505","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102793_b0510","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","article-title":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","volume":"36","author":"Kameda","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102793_b0515","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102793_b0520","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0525","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41409-023-01955-z","article-title":"The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT","volume":"58","author":"Tournilhac","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0530","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102793_b0535","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102793_b0540","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221143025","article-title":"Current state of CAR-T therapy for T-cell malignancies","volume":"13","author":"Luo","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102793_b0545","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/S2352-3026(20)30207-6","article-title":"The peripheral T-cell lymphomas: an unusual path to cure","volume":"7","author":"Ma","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0550","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0555","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0560","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102793_b0565","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"7347","key":"10.1016\/j.ctrv.2024.102793_b0570","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10066","article-title":"TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity","volume":"473","author":"Williams","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102793_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0230-6","article-title":"The cancer driver genes IDH1\/2, JARID1C\/ KDM5C, and UTX\/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism","volume":"51","author":"Chang","year":"2019","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102793_b0580","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0585","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0590","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0595","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","article-title":"IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment","volume":"41","author":"Leca","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102793_b0600","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102793_b0605","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102793_b0610","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/bloodadvances.2022009445","article-title":"Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma","volume":"7","author":"Kalac","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102793_b0615","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102793_b0620","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102793_b0625","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102793_b0630","first-page":"1422","article-title":"Targeting the T-cell lymphoma epigenome induces cell death, cancer testes antigens","volume":"20","author":"Scotto","year":"2021","journal-title":"Immune-Modulatory Signaling Pathways Mol Cancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T20:00:32Z","timestamp":1723665632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722400121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":126,"alternative-id":["S030573722400121X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102793","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-cell lymphoma: From biology to practice to the future","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102793"}}